IRLAB has announced that it has received a waiver from the European Medicines Agency, which means it does not have to perform studies of its lead asset, mesdopetam, in children. This would otherwise have been mandatory to support a European marketing authorisation application. Consequently, IRLAB can now focus its efforts in patient groups where Parkinson’s disease (PD) is more prevalent, such as in older populations, and hence avoid resource-demanding and lengthy studies in the paediatric population.
Mesdopetam is IRLAB’s lead clinical candidate, which is being developed as a potential treatment for levodopa-induced dyskinesias in PD patients. The company is currently preparing for Phase III.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment